ArticlePharmaceutical biology2023
Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis.
Article in Pharmaceutical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Global deletion ofbioRxiv : the preprint server for biology · 2026Article
- Anti-arthritic efficacy of geraniol and methotrexate via miRNA-driven NLRP3 inflammasome suppression in rat adjuvant-induced arthritis.Inflammopharmacology · 2026Article
- A comprehensive narrative review ofJournal of pharmaceutical analysis · 2026Review
- Icariin attenuates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome through SIRT3-mediated TFAM deacetylation.Frontiers in pharmacology · 2026Article
- PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies.Frontiers in immunology · 2026Review
- Effectiveness and Current Status of Icariin in the Treatment of Rotator Cuff Injury Associated with Osteoporosis.Current protein & peptide science · 2026Review
- Effect of Xuanfei Tongqiao acupuncture on nasal inflammation in rats with allergic rhinitis: modulation of long non-coding RNA growth arrest-specific transcript 5 methylation modification.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Light repair effect of polysaccharides component from white Ganoderma lucidum and Laminaria japonica fermentation broth attenuates epidermal barrier dysfunction via TRPV4-Keap-1/Nrf2 pathway.Bioresources and bioprocessing · 2025Article
- Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product-Based Therapies.Phytotherapy research : PTR · 2025Review
- Epigenetics and Herbs: Potential Therapeutic Strategies for Osteoarthritis of the Knee.Journal of pain research · 2025Review
- Pharmacological effects and mechanisms of medicine food homology species and active ingredients in ameliorating ovarian aging.Frontiers in nutrition · 2025Review
- The role of microRNAs in atopic dermatitis.Non-coding RNA research · 2024Review
- Review
- The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications.Clinical and experimental medicine · 2024Review
- Pathogenesis of Inflammation in Skin Disease: From Molecular Mechanisms to Pathology.International journal of molecular sciences · 2024Review
- Review
- Icariin ameliorates TNF-α/IFN-γ-induced oxidative stress, inflammatory response and apoptosis of human immortalized epidermal cells through the WTAP/SERPINB4 axis.Archives of dermatological research · 2024Article
- Long noncoding RNA MALAT1 in dermatologic disorders: a comprehensive review.Biomarkers in medicine · 2024Review
- Exploration of altered miRNA expression and function in MSC-derived extracellular vesicles in response to hydatid antigen stimulation.Frontiers in microbiology · 2024Article
- Effect of Chloroquine on Type 2 Inflammatory Response in MC903-Induced Atopic Dermatitis Mice.Clinical, cosmetic and investigational dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAtopic dermatitis (AD) is a common inflammatory skin disease characterized with hyperactivation of type 2 T helper (Th2) immune responses. Icariin is a flavonoid glucoside with anti-inflammatory activities, which has been used to treat multiple diseases.
objectiveThe present study investigates the underlying mechanisms by which icariin regulates Th2 responses and AD development. MATERIALS AND
methodsBALB/c mice were induced by DNFB to establish AD models, and injected with or without 10 mg/kg icariin for 2 weeks (i.p., daily). CD4
resultsIcariin ameliorated AD-like skin lesion, manifested as a significant decrease in dermatitis scores (from 8.00 ± 1.00 to 3.67 ± 0.58), serum IgE levels (from 3119.15 ± 241.81 to 948.55 ± 182.51 ng/mL), epidermal thickness (from 93.86 ± 4.61 to 42.67 ± 2.48 µm) and infiltration of mast cells (from 60.67 ± 3.21 cells to 36.00 ± 2.65 cells). Also, icariin inactivated NLRP3 inflammasome, inhibited Th2 skewing, reduced lncRNA MALAT1 expression, but elevated miR-124-3p expression DISCUSSION AND
conclusionsThe findings further improve our understanding of the mechanism by which icariin affects AD progression, and highlights the potential of icariin in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.